Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of RO5490248 Alone and in Combination with Bevacizumab in Advanced Solid Cancers
jRCT2080222032Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO5490248 in Nonhematologic neoplasms and solid neoplasms (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of RO5490248 alone and with bevacizumab and Maximum tolerated dose and/or recommended dose of RO5490248.
02
Drugs
RO5490248
03
Conditions
Nonhematologic neoplasmssolid neoplasms
Beyond the preview
Go deeper on jRCT2080222032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222032.